Effect of pravastatin on serum levels of matrix metalloproteinases-1, matrix metalloproteinases-9 in patients underwent percutaneous coronary intervention
- VernacularTitle:经皮冠状动脉介入治疗后普伐他汀对血清基质金属蛋白酶水平的影响
- Author:
Feifei LI
;
Li LI
;
Qiuhui LIU
;
Ruiyun LIU
- Publication Type:Journal Article
- Keywords:
percutaneous coronary intervention;
pravastatin;
coronary disease
- From:Journal of Third Military Medical University
2003;0(20):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influence of pravastatin on serum matrix metalloproteinases-1(MMP-1), MMP-9 and its role in prevention of restenosis following coronary intervention. Methods Totally 62 patients after percutaneous coronary intervention (PCI) were randomly assigned to receive 10 mg/d pravastatin in 24-48 h after PCI for 6 months (n=32) or no therapy (n=30) as control. The blood samples of all patients were examined at admission and 7, 21 d after administration of pravastatin. All patients received follow-up and coronary checking within 6 months. Results TIMI 3 flow was achieved in all cases and residual stenosis was less than 20%. No severe complications were found. ①The use of pravastatin after PCI could significantly reduce serum levels of MMP-1 and MMP-9 as compared with control group (P
